# Hidradenitis Suppurativa Study of Izokibep

> **NCT05905783** · PHASE3 · TERMINATED · sponsor: **ACELYRIN Inc.** · enrollment: 258 (actual)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Placebo
- **DRUG:** Izokibep

## Key facts

- **NCT ID:** NCT05905783
- **Lead sponsor:** ACELYRIN Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-06-22
- **Primary completion:** 2024-07-24
- **Final completion:** 2025-01-27
- **Target enrollment:** 258 (ACTUAL)
- **Why stopped:** Per our 13Aug24 press release, we announced discontinuation of internal development in this indication. This decision was not due to safety reasons.
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05905783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05905783, "Hidradenitis Suppurativa Study of Izokibep". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05905783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*